Ryplazim FDA Approval History
Last updated by Judith Stewart, BPharm on June 14, 2021.
FDA Approved: Yes (First approved June 4, 2021)
Brand name: Ryplazim
Generic name: plasminogen, human-tvmh
Company: Liminal BioSciences Inc.
Treatment for: Plasminogen Deficiency Type 1
Ryplazim (plasminogen, human-tvmh) is a plasma-derived plasminogen replacement therapy for the treatment of patients with plasminogen deficiency type 1 (hypoplasminogenia).
Development Timeline for Ryplazim
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.